{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-026269","form_type":"8-K","ticker":"BIXT","cik":"0001445815","company_name":"BIOXYTRAN, INC","filed_at":"2024-07-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.088117+00:00","generated_at":"2026-05-31T23:19:48.368405+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"confidence":"medium","headline":"Bioxytran announces Springer book linking hyperbaric oxygenation to BXT-25 drug","bullets":["Book by Prof. Mayevsky published by Springer; covers hyperbaric oxygenation and mitochondrial activity.","BXT-25 is an acellular oxygen carrier (AOC) 5,000x smaller than RBC; aims to replace HBOT.","MDX Viewer (FDA-approved) measures tissue oxygenation via Brain Metabolic Score (BMS).","BMS used as biomarker to demonstrate efficacy in upcoming stroke and Alzheimer's trials.","Company expects coupling BXT-25 with MDX Viewer could shorten clinical trial timelines."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-026269","json":"https://secwatch.observer/filing/0001493152-24-026269.json","markdown":"https://secwatch.observer/filing/0001493152-24-026269.md","text":"https://secwatch.observer/filing/0001493152-24-026269.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1445815/000149315224026269/0001493152-24-026269-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1445815/000149315224026269/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T23:19:48.368405+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}